Lipid apheresis, indications, and principles

Journal of Clinical Apheresis

Volumn 26, Issue 5, 2011, Pages 269-275

  Winters, Jeffrey L ^a  

^a MAYO CLINIC   (United States)

Author keywords

apolipoprotein B; familial hypercholesterolemia; LDL apheresis; low density lipoprotein; plasma exchange

Indexed keywords

ACID CITRATE DEXTROSE; APOLIPOPROTEIN B; DEXTRAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; POLYACRYLIC ACID; STEROID; TURMERIC;

ALLERGIC REACTION; ANGIOGRAPHY; AORTA STENOSIS; APHERESIS; ATHEROSCLEROSIS; BLEEDING; BLOOD FILTRATION; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEXTRAN SULFATE DIRECT PERFUSION; DIET; DIET THERAPY; DISEASE COURSE; DOUBLE FILTRATION PLASMAPHERESIS; DRUG HALF LIFE; DYSPNEA; FAMILIAL HYPERCHOLESTEROLEMIA; FOCAL GLOMERULOSCLEROSIS; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION; HETEROZYGOTE; HOMOZYGOTE; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; HYPOTENSION; IMMUNOADSORPTION; INTRAVASCULAR ULTRASOUND; LIPID METABOLISM; LOW DENSITY LIPOPROTEIN APHERESIS; MEDICAL INSTRUMENTATION; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMAPHERESIS; POLYACRYLATE COATED POLACRYLAMIDE DIRECT PERFUSION; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHOCK; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADSORPTION; ADULT; APOLIPOPROTEINS B; BLOOD COMPONENT REMOVAL; CHILD; DEXTRAN SULFATE; FILTRATION; GENE DOSAGE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEINS, LDL; PERFUSION; TREATMENT OUTCOME;

EID: 81155160849     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20299     Document Type: Review

References (36)

1. Bhatnagar D,. Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes. Ann Clin Biochem 2006; 43: 441-456. (Pubitemid 44808269)
2. Ueda M,. Familial hypercholesterolemia. Mol Genet Metab 2005; 86: 423-426. (Pubitemid 41796482)
3. Soutar AK, Naoumova RP,. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-225. (Pubitemid 46502094)
4. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE,. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br Heart J 1980; 43: 680-688. (Pubitemid 10058936)
5. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A, Goto Y, and LARS Investigators. Regression of coronary atherosclerosis by combined LDL apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992; 95: 1-13.
6. Thompson GR, Miller JP, Breslow JL,: Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J 1985; 291: 1671-1673. (Pubitemid 16211891)
7. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz B,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.
8. Stoffel W, Borberg H, Greve V,. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2: 1005-1007. (Pubitemid 11027575)
9. Klingel R, Mausfeld P, Fassbender C, Goehlen B,. Lipidfiltration-safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004; 30: 245-254. (Pubitemid 38698339)
10. Siami GA, Siami FS,. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher 2001; 5: 315-320. (Pubitemid 33062681)
11. Parhofer KG, Geiss HC, Schwandt P,. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 2000; 4: 381-385.
12. Yokoyama S,. Treatment of hypercholesterolemia by chemical adsorption of lipoproteins. J Clin Apher 1988; 4: 66-71.
13. Yamamoto A, Kojima S, Shiba-Harada M, Kawaguchi A, Hatanaka K,. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 1992; 16: 177-181.
14. Riesen WF,. Experience with low-density lipoprotein apheresis by polyclonal and monoclonal anti-apolipoprotein B antibodies and by dextran sulfate cellulose. Curr Stud Hematol Blood Transfus 1990; 57: 208-219. (Pubitemid 20370050)
15. Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R, Takada S, Oonishi M,. A new low-density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987; 68: 19-25. (Pubitemid 17151101)
16. Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, Yagi K, Kamon N, Miyamoto S, Takegoshi T, Mabuchi H, Takeda R, Tani N, Takada S,. Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993; 100: 65-74. (Pubitemid 23166009)
17. Bambauer R, Schiel R, Latza R,. Low-density lipoprotein apheresis: an overview. Ther Apher Dial 2003; 7: 382-390. (Pubitemid 37082024)
18. Matsuda Y, Malchesky PS, Nose Y,. Assessment of currently available low-density lipoprotein apheresis systems. Artif Organs 1994; 18: 93-99. (Pubitemid 24053466)
19. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W,. LDL hemoperfusion-a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 1997; 21: 977-981.
20. Bosch T, Lennetz A, Schenzle D, Dräger J,. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apher 2002; 17: 161-169. (Pubitemid 36015429)
21. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG,. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003; 27: 1116-1122. (Pubitemid 38037567)
22. Tasaki H, Yamashita K, Saito Y, Bujo H, Daida H, Mabuchi H, Tominaga Y, Matsuzaki M, Fukunari K, Nakazawa R, Tsuji M, Kawade Y, Yamamoto S, Ueda Y, Takayama K,. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. Ther Apher Dial 2006; 10: 32-41.
23. Owen HG, Brecher ME,. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 891-894. (Pubitemid 24308112)
24. Adamski J, Jamensky L, Ross J, Siegel DL, Sachais BS,. Anaphylactoid-like reactions in a patient with hyperLp(a)lipidemia undergoing LDL apheresis with dextran sulfate adsorption and herbal therapy with the spice turmeric. J Clin Apher 2010; 25: 354-357.
25. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-255.
26. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandry P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S,. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208: 317-321.
27. Mabuchi H, Koizumi J, Shimzu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T,. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82: 1489-1495. (Pubitemid 29006472)
28. Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, Fujii T, Sakuma I, Fukami K, Honda T, Ogawa H, Yamagishi M,. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 220-227.
29. Aengevaeren WRM, Kroon AA, Stalenhoef AFH, Uijen GJH, Van der Werf T,. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. JACC 1996; 28: 1696-1704.
30. Kroon AA, van Asten WN, Stalenhoef AF,. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125: 945-954. (Pubitemid 26424522)
31. Park JW, Merz M, Braun P,. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16: 290-297. (Pubitemid 27138293)
32. Thompson J, Thompson PD,. A systemic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 1006; 189: 31-38.
33. Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S,. Treatment of symptomatic hyperLp(a) lipidemia with LDL-apheresis vs. usual care. Transfus Apher Sci 2010; 42: 21-26.
34. Suckfüll M, the Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomized multicentre trial. Lancet 2002; 360: 1811-1817. (Pubitemid 35449418)
35. Yokoyama K, Sakai S, Sugematsu T, Takemoto F, Hara S, Kawaguchi Y, Hosoya T,. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 1998; 50: 1-7. (Pubitemid 28349767)
36. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y,. Low-density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int 1999; 71 (Suppl): S122-S125. (Pubitemid 29304830)